TY - JOUR
T1 - Diagnosis of Peanut Allergy in Preschool Children
T2 - The Impact of Skin Testing With a Novel Composition of Peanuts
AU - Kidon, Mona I.
AU - Yahia, Soad Haj
AU - Machnes-Maayan, Diti
AU - Levy, Yael
AU - Frizinsky, Shirli
AU - Maoz-Segal, Ramit
AU - Offenganden, Irena
AU - Kenett, Ron S.
AU - Agmon-Levin, Nancy
AU - Hovav, Ran
N1 - Publisher Copyright:
Copyright © 2021 Kidon, Yahia, Machnes-Maayan, Levy, Frizinsky, Maoz-Segal, Offenganden, Kenett, Agmon-Levin and Hovav.
PY - 2021/11/30
Y1 - 2021/11/30
N2 - Peanut allergy is an increasing concern in younger children. Available bedside diagnostic tools, i.e., prick tests with commercial extracts or peanut-containing foods have only limited predictive values. In a cohort of preschoolers with both a history of allergic reactions and sensitization to peanut proteins, we aimed to characterize the impact of skin tests with a novel composition of peanuts LPP-MH. Almost one quarter (27/110) of preschool children, with a history of allergic reactions to peanuts and positive standard IgE-mediated tests for peanut allergy, can tolerate the reintroduction of peanut proteins into their diet after resolving their allergy and, thus, can avoid adverse health outcomes associated with the false diagnosis. In the younger age group, a quarter of peanut allergic children, display a relatively high threshold, potentially enabling an easier and safer oral immunotherapy protocol in this window of opportunity in childhood. The use of the novel diagnostic skin test, LPP-MH, significantly improves the predictive value of outpatient evaluation for the outcomes of peanut challenge as well as the expected threshold at which the PA child will react, thus, making for a better informed decision of how, when, and where to challenge.
AB - Peanut allergy is an increasing concern in younger children. Available bedside diagnostic tools, i.e., prick tests with commercial extracts or peanut-containing foods have only limited predictive values. In a cohort of preschoolers with both a history of allergic reactions and sensitization to peanut proteins, we aimed to characterize the impact of skin tests with a novel composition of peanuts LPP-MH. Almost one quarter (27/110) of preschool children, with a history of allergic reactions to peanuts and positive standard IgE-mediated tests for peanut allergy, can tolerate the reintroduction of peanut proteins into their diet after resolving their allergy and, thus, can avoid adverse health outcomes associated with the false diagnosis. In the younger age group, a quarter of peanut allergic children, display a relatively high threshold, potentially enabling an easier and safer oral immunotherapy protocol in this window of opportunity in childhood. The use of the novel diagnostic skin test, LPP-MH, significantly improves the predictive value of outpatient evaluation for the outcomes of peanut challenge as well as the expected threshold at which the PA child will react, thus, making for a better informed decision of how, when, and where to challenge.
KW - allergy
KW - diagnosis
KW - early life
KW - high threshold
KW - peanut
KW - preschool
UR - http://www.scopus.com/inward/record.url?scp=85121339101&partnerID=8YFLogxK
U2 - 10.3389/fped.2021.739224
DO - 10.3389/fped.2021.739224
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 34917557
AN - SCOPUS:85121339101
SN - 2296-2360
VL - 9
JO - Frontiers in Pediatrics
JF - Frontiers in Pediatrics
M1 - 739224
ER -